Stella Diagnostics, Inc. operates as a molecular diagnostics-based organization, which focuses on improving patient management strategies. The company is headquartered in Salt Lake City, Utah. The company went IPO on 2003-07-29. The Company’s proprietary technology is based on rigorous research by domain experts and practicing physicians and can notify providers if common diseases of the esophagus like GERD and Barrett’s esophagus express proteins associated with normal or carcinogenic processes. Its panel of biomarkers and targeted proteomics method, the company can better inform gastroenterologists, surgical oncologists and pathologists which patients are high risk for disease progression into precancer or cancer. The predictive panel will be offered as a Laboratory Developed Test (LDT) in a CAP/CLIA Certified moderate complexity laboratory. Its subsidiaries include SLDX, Inc. and Galaxy Pharmaceuticals LLC.
최신 재무제표(Form-10K)에 따르면, Universal Health Realty Income Trust의 총 자산은 $0이며, 순손실입니다.
SLDX의 주요 재무 비율은 무엇인가요?
Universal Health Realty Income Trust의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.
Stella Diagnostics Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Universal Health Realty Income Trust 주요 수익원은 Facilities이며, 최신 수익 발표에서 수익은 93,292,000입니다. 지역별로는 United States이 Universal Health Realty Income Trust의 주요 시장이며, 수익은 99,011,000입니다.
Stella Diagnostics Inc은 수익성이 있나요?
no, 최신 재무제표에 따르면 Universal Health Realty Income Trust의 순손실은 $0입니다.
Stella Diagnostics Inc에 부채가 있나요?
no, Universal Health Realty Income Trust의 부채는 0입니다.
Stella Diagnostics Inc의 발행 주식은 몇 주인가요?
Universal Health Realty Income Trust의 총 발행 주식은 0주입니다.